Diabetic Neuropathy Market

Diabetic Neuropathy Market (Disorder Type - Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, and Focal Neuropathy; Treatment Type - Drugs (Analgesic (Topical, Opioid, and NSAIDs), Antidepressants (TCAs, SNRIs, and SSRIs), and Anticonvulsant Drugs (Gabapentin, Pregabalin, and Topiramate), Radiotherapy (Transcutaneous Electrical Nerve Stimulation (TENS)), and Physiotherapy; Distribution Channel - Hospitals, Clinics, Retail Pharmacy, and Online Pharmacy) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Global Diabetic Neuropathy Market: Snapshot

A handful of international and local manufacturers with limited shares dominate the global diabetic neuropathy market. This makes the competitive landscape semi-consolidated in nature. The competition among them is intense with most spending time and money on research and development of more effective neuropathy drugs.

The global diabetic neuropathy market is being primarily driven by changing lifestyles which has mostly resulted in unhealthy dietary habits and patterns. As per WHO, about 422 were afflicted by diabetes in 2014. Apart from that, other growth drivers in the market are the approval of novel drugs to treat neuropathic pain and supportive reimbursement policies.

Drugs administered to treat neuropathic pain, however, so far have had only limited success in terms of pain relief. This coupled with erroneous diagnosis or selection of treatment and side effects and rising cost of diabetic neuropathy treatment drugs are posing a hindrance to the market for diabetic neuropathy market.

A report by Transparency Market Research, forecasts the global diabetic neuropathy market to become worth US$5.718 bn by 2024 from US$ 3.6 bn in 2016 by rising at a steady CAGR of 5.4% between 2017 and 2025.

diabetic neuropathy market

 

Peripheral Neuropathy to Retain its Dominant Share by Clocking Maximum Growth

Peripheral neuropathy, autonomic neuropathy, proximal neuropathy, and focal neuropathy are the prominent disorders in the global diabetic neuropathy market. Peripheral neuropathy, of them, accounts for almost half the share in the market at present. In the near future it is predicted to grow its share marginally by surpassing all other segments in terms of growth rate. The report by TMR predicts the segment to clock a 5.7% CAGR from 2017 to 2025 because of the high prevalence of diabetic neuropathy.

Proximal neuropathy follows peripheral neuropathy when it comes to market share in the global diabetic neuropathy market. This is because proximal diabetic neuropathy is the most commonly found disorder in type 2 diabetes. The segment was worth US$885.6 mn in 2016 and will likely rise to US$1.405 mn by 2025 by expanding at a CAGR of 5.4% from 2017 to 2025.

Major Players Target North America Market Having Large Patient Pool

Key regional segments in the global diabetic neuropathy market are North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Among them, North America accounted for a market leading share of 34.9% in 2016. This is mainly on account of the large pool of patients who have been diagnosed and the expensiveness of therapy. In fact, keen companies are eyeing the market in U.S. in the region to up sales and revenues. The market in North America was worth US$1.071 bn in 2016 and rising at 5.3% CAGR between 2017 and 2025, it is slated to become worth US$1.68 bn by 2025.

Europe trails North America in the global diabetic neuropathy market in terms of size. Its market has been mostly driven by the rising occurrence of diabetic neuropathy and a growing pool of elderly, particularly in countries of Italy, Germany, France, and the U.K. In terms of growth rate, however, the market is Asia Pacific is predicted to outshine all others. Powered primarily by China, Asia Pacific will likely clock a CAGR of 6.7% on account of the growing number of healthcare awareness programs, hospitals equipped with radiology devices to treat diabetic neuropathy, and a large pool of patients.

Some of the key names operating in the market are Pfizer, Inc., Johnson & Johnson, Boehringer Ingelheim GmbH, NeuroMetrix, Inc., Astellas Pharma Inc., Eli Lilly and Company, GlaxoSmithKline plc, Lupin Limited, Depomed, Inc., Glenmark Pharmaceuticals Ltd, and Arbor Pharmaceuticals, LLC.

Diabetic Neuropathy Market will Rise Remarkably Owing to Increasing Number of Diabetic Population

The changing lifestyle and increasing adoption of unhealthy eating habits is prognosticated to attract high revenues for the global diabetic neuropathy market. Medications directed to treat neuropathic torment, nonetheless, so far have had just restricted accomplishment as far as relief from discomfort. This combined with wrong finding or choice of treatment and results and increasing expense of diabetic neuropathy treatment drugs are representing an obstruction to the market for diabetic neuropathy market.

Diabetic patients are without a doubt incredibly helpless against genuine inconveniences, whenever tainted by the COVID-19 infection. The disease can cause inner expanding and furthermore increment aggravation among diabetic patients. It is, along these lines, basic for medical clinics, facilities and careful focuses to guarantee that such complexities are alleviated by giving progressed clinical consideration. Luckily, driving makers in the diabetes area have announced that the COVID-19 isn't affecting their present assembling and appropriation abilities for indispensable infusions like insulin.

Diabetic neuropathy alludes to harm of nerves influencing individuals with diabetes. Various kinds of nerve harm lead to various sorts of side effects. Manifestations may go from deadness and agony in one's feet to issues with the day by day elements of one's inward organs, like bladder and heart. Indications change as per the kind of diabetic neuropathy one has. In diabetes patients, undeniable degree of blood glucose, likewise also called glucose, along with significant degrees of fats in the blood can harm one's nerves with time. Expanded predominance of diabetes is probably going to impel development of the diabetic neuropathy market.

One of the significant variables that are assessed to shape the fate of the worldwide diabetic neuropathy market is the ascent in the number maturing individuals who are inclined to experience the ill effects of the said ailment. Besides, ascend in the innovative work exercises for the advancement of new medications to help treat the problem of diabetic neuropathy is probably going to support development of the market over the time of projection.

The Global Diabetic Neuropathy Market is segmented as given below:

by Product

  • Peripheral Neuropathy
  • Autonomic Neuropathy
  • Proximal Neuropathy
  • Focal Neuropathy

by Treatment Type

  • Drug
    • Analgesic
      • Topical
        • Capsaicin
        • Others
      • Opioids
        • Morphine
        • Others
      • NSAIDs
        • Ibuprofen
        • Naproxen
        • Others
    • Antidepressant
      • TCAs
        • Amitriptyline
        • Imipramine
        • Others
      • SNRIs
        • Duloxetine
        • Others
      • SSRIs
        • Citalopram
        • Paroxetin
        • Others
    • Anticonvulsants
      • Gabapentin
      • Pregabalin
      • Topimarate
      • Others
    • Other Drugs
  • Radiotherapy
    • TENS
    • Others
  • Physiotherapy

by Distribution Channel

  • Hospitals
  • Clinics
  • Retail Pharmacy
  • Online Pharmacy

by Geography

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • U.K.
    • Russia
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • India
    • China
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC countries
    • South Africa
    • Rest of Middle East & Africa
  • Online

    1. Preface
         1.1. Market Definition and Scope
         1.2. Market Segmentation
         1.3. Key Research Objectives
         1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary : Global Diabetic Neuropathy Market 

    4. Market Overview
         4.1. Introduction
                 4.1.1 Product Definition
                 4.1.2 Industry Evolution / Developments
         4.2 Overview
         4.3 Key Market Indicators
                 4.3.1 Region/Country Specific
                 4.3.2 Product/Application/Disease Indication Specific
                 4.3.3 Target Market Specific – Global Scenario
         4.4 Market Dynamics
                 4.4.1 Drivers
                 4.4.2 Restraints
                 4.4.3 Opportunity
         4.5 Global Diabetic Neuropathy Market  Analysis and Forecasts, 2015–2025
                 4.5.1 Market Revenue Projections (US$ Mn)
         4.6 Diabetic Neuropathy Market  - Global Supply Demand Scenario
         4.7 Porter’s Five Force Analysis
         4.8 Market Outlook
         4.9 Diabetic Neuropathy Market : Pipeline Analysis
         4.10 Diabetic Neuropathy : Prevalence Data & Percentage of Patient Receiving Treatment

    5. Global Diabetic Neuropathy Analysis and Forecasts, By Disorder Type 
         5.1 Introduction & Definition     
         5.2 Key Findings / Developments
         5.3 Key Trends
         5.4 Market Value Forecast By Disorder Type , 2015–2025
                 5.4.1 Peripheral Neuropathy
                 5.4.2 Autonomic Neuropathy
                 5.4.3 Proximal Neuropathy
                 5.4.4 Focal Neuropathy 
         5.5 Market Attractiveness By Disorder Type 

    6. Global Diabetic Neuropathy Analysis and Forecasts, By Treatment Type 
         6.1 Introduction & Definition     
         6.2 Key Findings / Developments
         6.3 Key Trends
         6.4 Market Value Forecast By Treatment Type, 2015–2025
                 6.4.1 Drug
                          6.4.1.1 Analgesic
                                     6.4.1.1.1 Topical
                                                  6.4.1.1.1.1  Capsaicin
                                                  6.4.1.1.1.2  Others
                                     6.4.1.1.2 Opioids
                                                  6.4.1.1.2.1 Morphine
                                                  6.4.1.1.2.2 Others
                                     6.4.1.1.3 NSAIDs
                                                  6.4.1.1.3.1 Ibuprofen
                                                  6.4.1.1.3.2 Naproxen
                                                  6.4.1.1.3.3 Others
                          6.4.1.2 Antidepressant
                                     6.4.1.2.1 TCAs
                                                  6.4.1.2.1.1 Amitriptyline
                                                  6.4.1.2.1.2 Imipramine
                                                  6.4.1.2.1.3 Others
                                     6.4.1.2.2 SNRIs
                                                  6.4.1.2.2.1 Duloxetine
                                                  6.4.1.2.2.2 Others
                                     6.4.1.2.3 SSRIs
                                                  6.4.1.2.3.1 Citalopram
                                                  6.4.1.2.3.2 Paroxetin
                                                  6.4.1.2.3.3 Others
                          6.4.1.3. Anticonvulsants
                                     6.4.1.3.1 Gabapentin
                                     6.4.1.3.2 Pregabalin
                                     6.4.1.3.3 Topimarate
                                     6.4.1.3.4 Others
                          6.4.1.4. Other Drugs
                 6.4.2 Radiotherapy
                          6.4.2.1 TENS
                          6.4.2.2 Other
                 6.4.3 Physiotherapy
         6.5 Market Attractiveness By Treatment 

    7. Global Diabetic Neuropathy Market  Analysis and Forecasts, By Distribution Channel
         7.1 Introduction & Definition
         7.2 Key Findings / Developments
         7.3 Key Trends
         7.4 Market Value Forecast By Distribution Channel, 2015–2025
                 7.4.1 Hospitals
                 7.4.2 Clinics
                 7.4.3 Retail Pharmacy 
                 7.4.4 Online Pharmacy 
         7.5 Market Attractiveness By Distribution Channel

    8. Global Diabetic Neuropathy Market  Analysis and Forecasts, By Region
         8.1 Key Findings
         8.2 Policies and Regulations
         8.3 Market Value Forecast By Region
                 8.3.1 North America 
                 8.3.2 Europe 
                 8.3.3 Asia Pacific 
                 8.3.4 Latin America 
                 8.3.5 Middle East and Africa 
         8.4 Market Attractiveness By Country/Region

    9. North America Diabetic Neuropathy Market  Analysis and Forecast
         9.1 Introduction
                 9.1.1 Key Findings
                 9.1.2 Policies and Regulations
                 9.1.3 Key Trends
         9.2 Market Value Forecast By Disorder Type, 2015–2025
                 9.2.1 Peripheral Neuropathy
                 9.2.2 Autonomic Neuropathy
                 9.2.3 Proximal Neuropathy
                 9.2.4 Focal Neuropathy 
         9.3 Market Value Forecast By Treatment Type, 2015–2025
                 9.3.1 Drug
                          9.3.1.1 Analgesic
                                     9.3.1.1.1 Topical
                                                  9.3.1.1.1.1 Capsaicin
                                                  9.3.1.1.1.2 Others
                                     9.3.1.1.2 Opioids
                                                  9.3.1.1.2.1 Morphine
                                                  9.3.1.1.2.2 Others
                                     9.3.1.1.3 NSAIDs
                                                  9.3.1.1.3.1 Ibuprofen
                                                  9.3.1.1.3.2 Naproxen
                                                  9.3.1.1.3.3 Others
                          9.3.1.2. Antidepressant
                                     9.3.1.2.1 TCAs
                                                  9.3.1.2.1.1 Amitriptyline
                                                  9.3.1.2.1.2 Imipramine
                                                  9.3.1.2.1.3 Others
                                     9.3.1.2.2 SNRIs
                                                  9.3.1.2.2.1 Duloxetine
                                                  9.3.1.2.2.2 Others
                                     9.3.1.2.3 SSRIs
                                                  9.3.1.2.3.1 Citalopram
                                                  9.3.1.2.3.2 Paroxetin
                                                  9.3.1.2.3.3 Others
                          9.3.1.3. Anticonvulsants
                                     9.3.1.3.1 Gabapentin
                                     9.3.1.3.2 Pregabalin
                                     9.3.1.3.3 Topimarate
                                     9.3.1.3.4 Others
                          9.3.1.4. Other Drugs
                 9.4.2. Radiotherapy
                          9.4.2.1. TENS
                          9.4.2.2. Other
                 9.4.3. Physiotherapy
         9.4. Market Value Forecast By Distribution Channel, 2015–2025
                 9.4.1. Hospitals
                 9.4.2. Clinics
                 9.4.3. Retail Pharmacy 
                 9.4.4. Online Pharmacy 
         9.5. Market Value Forecast By Country , 2015–2025
                 9.5.1. U.S.
                 9.5.2. Canada
         9.6. Market Attractiveness Analysis 
                 9.6.1. By Disorder Type
                 9.6.2. By Treatment Type
                 9.6.3. By Distribution Channel
                 9.6.5. By Country

    10. Europe Diabetic Neuropathy Market  Analysis and Forecast
         10.1. Introduction
                 10.1.1. Key Findings
                 10.1.2. Policies and Regulations
                 10.1.3. Key Trends
         10.2. Market Value Forecast By Disorder Type, 2015-2025
                 10.2.1. Peripheral Neuropathy
                 10.2.2. Autonomic Neuropathy
                 10.2.3. Proximal Neuropathy
                 10.2.4. Focal Neuropathy 
         10.3. Market Value Forecast By Treatment Type, 2015–2025
                 10.3.1. Drug
                          10.3.1.1. Analgesic
                                      10.3.1.1.1 Topical
                                                  10.3.1.1.1.1 Capsaicin
                                                  10.3.1.1.1.2 Others
                                     10.3.1.1.2 Opioids
                                                  10.3.1.1.2.1 Morphine
                                                  10.3.1.1.2.2 Others
                                     10.3.1.1.3 NSAIDs
                                                  10.3.1.1.3.1 Ibuprofen
                                                  10.3.1.1.3.2 Naproxen
                                                  10.3.1.1.3.3 Others
                          10.3.1.2 Antidepressant
                                     10.3.1.2.1 TCAs
                                                  10.3.1.2.1.1 Amitriptyline
                                                  10.3.1.2.1.2 Imipramine
                                                  10.3.1.2.1.3 Others
                                     10.3.1.2.2 SNRIs
                                                  10.3.1.2.2.1 Duloxetine
                                                  10.3.1.2.2.2 Others
                                     10.3.1.2.3 SSRIs
                                                  10.3.1.2.3.1 Citalopram
                                                  10.3.1.2.3.2 Paroxetin
                                                  10.3.1.2.3.3 Others
                          10.3.1.3 Anticonvulsants
                                     10.3.1.3.1 Gabapentin
                                     10.3.1.3.2 Pregabalin
                                     10.3.1.3.3 opimarate
                                     10.3.1.3.4 Others
                          10.3.1.4 Other Drugs
                 10.3.2 Radiotherapy
                          10.3.2.1 TENS
                          10.3.2.2 Other
                 10.4.3 Physiotherapy
         10.4 Market Value Forecast By Distribution Channel, 2015–2025
                 10.4.1 Hospitals
                 10.4.2 Clinics
                 10.4.3 Retail Pharmacy 
                 10.4.4 Online Pharmacy 
         10.5 Market Value Forecast By Country, 2015–2025
                 10.5.1 Germany
                 10.5.2 France
                 10.5.3 U.K.
                 10.5.4 Spain
                 10.5.5 Italy
                 10.5.6 Russia
                 10.5.7 Rest of Europe
         10.6 Market Attractiveness Analysis 
                 10.6.1 By Disorder Type 
                 10.6.2 By Treatment Type 
                 10.6.3 By Distribution Channel
                 10.6.4 By Country

    11. Asia Pacific Diabetic Neuropathy Market  Analysis and Forecast
         11.1 Introduction
                 11.1.1 Key Findings
                 11.1.2 Policies and Regulations
                 11.1.3 Key Trends
         11.2 Market Value Forecast By Disorder Type , 2015–2025
                 11.2.1 Peripheral Neuropathy
                 11.2.2 Autonomic Neuropathy
                 11.2.3 Proximal Neuropathy
                 11.2.4 Focal Neuropathy 
         11.3 Market Value Forecast By Treatment Type, 2015–2025
                 11.3.1 Drug
                          11.3.1.1 Analgesic
                                     11.3.1.1.1 Topical
                                                  11.3.1.1.1.1 Capsaicin
                                                  11.3.1.1.1.2 Others
                                     11.3.1.1.2 Opioids
                                                  11.3.1.1.2.1 Morphine
                                                  11.3.1.1.2.2 Others
                                     11.3.1.1.3 NSAIDs
                                                  11.3.1.1.3.1 Ibuprofen
                                                  11.3.1.1.3.2 Naproxen
                                                  11.3.1.1.3.3 Others
                          11.3.1.2 Antidepressant
                                     11.3.1.2.1 TCAs
                                                  11.3.1.2.1.1 Amitriptyline
                                                  11.3.1.2.1.2 Imipramine
                                                  11.3.1.2.1.3 Others
                                     11.3.1.2.2 SNRIs
                                                  11.3.1.2.2.1 Duloxetine
                                                  11.3.1.2.2.2 Others
                                     11.3.1.2.3 SSRIs
                                                  11.3.1.2.3.1 Citalopram
                                                  11.3.1.2.3.2 Paroxetin
                                                  11.3.1.2.3.3 Others
                          11.3.1.3 Anticonvulsants
                                     11.3.1.3.1 Gabapentin
                                     11.3.1.3.2 Pregabalin
                                     11.3.1.3.3 Topimarate
                                     11.3.1.3.4 Others
                          11.3.1.4 Other Drugs
                 11.3.2 Radiotherapy
                          11.3.2.1 TENS
                          11.3.2.2 Other
                 11.3.3 Physiotherapy
         11.4 Market Value Forecast By Distribution Channel , 2015–2025
                 11.4.1 Hospitals
                 11.4.2 Clinics
                 11.4.3 Retail Pharmacy 
                 11.4.4 Online Pharmacy 
         11.5 Market Value Forecast By Country , 2015–2025
                 11.5.1 China
                 11.5.2 Japan
                 11.5.3 India
                 11.5.4 Australia & New Zealand
                 11.5.5 Rest of Asia Pacific
         11.6 Market Attractiveness Analysis 
                 11.6.1 By Disorder Type
                 11.6.2 By Treatment Type
                 11.6.3 By Distribution Channel
                 11.6.4 By Country
                 
    12. Latin America Diabetic Neuropathy Market  Analysis and Forecast
         12.1 Introduction
                 12.1.1 Key Findings
                 12.1.2 Policies and Regulations
                 12.1.3 Key Trends
         12.2 Market Value Forecast By Disorder Type , 2015–2025
                 12.2.1 Peripheral Neuropathy
                 12.2.2 Autonomic Neuropathy
                 12.2.3 Proximal Neuropathy
                 12.2.4 Focal Neuropathy 
         12.3 Market Value Forecast By Treatment Type, 2015–2025
                 12.3.1 Drug
                          12.3.1.1 Analgesic
                                     12.3.1.1.1 Topical
                                                  12.3.1.1.1.1 Capsaicin
                                                  12.3.1.1.1.2 Others
                                     12.3.1.1.2 Opioids
                                                  12.3.1.1.2.1 Morphine
                                                  12.3.1.1.2.2 Others
                                     12.3.1.1.3 NSAIDs
                                                  12.3.1.1.3.1 Ibuprofen
                                                  12.3.1.1.3.2 Naproxen
                                                  12.3.1.1.3.3 Others
                          12.3.1.2 Antidepressant
                                     12.3.1.2.1 TCAs
                                                  12.3.1.2.1.1 Amitriptyline
                                                  12.3.1.2.1.2 Imipramine
                                                  12.3.1.2.1.3 Others
                                     12.3.1.2.2 SNRIs
                                                  12.3.1.2.2.1 Duloxetine
                                                  12.3.1.2.2.2 Others
                                     12.3.1.2.3 SSRIs
                                                  12.3.1.2.3.1 Citalopram
                                                  12.3.1.2.3.2 Paroxetin
                                                  12.3.1.2.3.3 Others
                          12.3.1.3 Anticonvulsants
                                     12.3.1.3.1 Gabapentin
                                     12.3.1.3.2 Pregabalin
                                     12.3.1.3.3 Topimarate
                                     12.3.1.3.4 Others
                          12.3.1.4 Other Drugs
                 12.3.2 Radiotherapy
                          12.3.2.1 TENS
                          12.3.2.2 Other
                 12.3.3 Physiotherapy
         12.4 Market Value Forecast By Distribution Channel , 2015–2025
                 12.4.1 Hospitals
                 12.4.2 Clinics
                 12.4.3 Retail Pharmacy 
                 12.4.4 Online Pharmacy 
         12.5 Market Value Forecast By Country , 2015–2025
                 12.5.1 Brazil
                 12.5.2 Mexico
                 12.5.3 Rest of Latin America
         12.6 Market Attractiveness Analysis 
                 12.6.1 By Disorder Type 
                 12.6.2 By Treatment Type 
                 12.6.3 By Distribution Channel 
                 12.6.4 By Country

    13. Middle East and Africa Diabetic Neuropathy Market  Analysis and Forecast
         13.1. Introduction
                 13.1.1 Key Findings
                 13.1.2 Policies and Regulations
                 13.1.4 Key Trends
         13.2. Market Value Forecast By Disorder Type, 2015–2025
                 13.2.1 Peripheral Neuropathy
                 13.2.2 Autonomic Neuropathy
                 13.2.3 Proximal Neuropathy
                 13.2.4 Focal Neuropathy 
         13.3. Market Value Forecast By Treatment Type, 2015–2025
                 13.3.1 Drug
                          13.3.1.1 Analgesic
                                     13.3.1.1.1 Topical
                                                  13.3.1.1.1.1 Capsaicin
                                                  13.3.1.1.1.2 Others
                                     13.3.1.1.2 Opioids
                                                  13.3.1.1.2.1 Morphine
                                                  13.3.1.1.2.2 Others
                                     13.3.1.1.3 NSAIDs
                                                  13.3.1.1.3.1 Ibuprofen
                                                  13.3.1.1.3.2 Naproxen
                                                  13.3.1.1.3.3 Others
                          13.3.1.2 Antidepressant
                                     13.3.1.2.1 TCAs
                                                  13.3.1.2.1.1 Amitriptyline
                                                  13.3.1.2.1.2 Imipramine
                                                  13.3.1.2.1.3 Others
                                     13.3.1.2.2 SNRIs
                                                  13.3.1.2.2.1 Duloxetine
                                                  13.3.1.2.2.2 Others
                                     13.3.1.2.3 SSRIs
                                                  13.3.1.2.3.1 Citalopram
                                                  13.3.1.2.3.2 Paroxetin
                                                  13.3.1.2.3.3 Others
                          13.3.1.3 Anticonvulsants
                                     13.3.1.3.1 Gabapentin
                                     13.3.1.3.2 Pregabalin
                                     13.3.1.3.3 Topimarate
                                     13.3.1.3.4 Others
                          13.3.1.4 Other Drugs
                 13.3.2 Radiotherapy
                          13.3.2.1 TENS
                          13.3.2.2 Other
                 13.3.3 Physiotherapy
         13.4 Market Value Forecast By Distribution Channel , 2015–2025
                 13.4.1 Hospitals
                 13.4.2 Clinics
                 13.4.3 Retail Pharmacy 
                 13.4.4 Online Pharmacy 
         13.5 Market Value Forecast By Country , 2015–2025
                 13.5.1 GCC Countries
                 13.5.2 South Africa
                 13.5.3 Rest of Middle East and Africa
         13.6 Market Attractiveness Analysis 
                 13.6.1 By Disorder Type 
                 13.6.2 By Treatment 
                 13.6.3 By Distribution Channel 
                 13.6.4 By Country

    14. Competition Landscape
         14.1 Market Player – Competition Matrix (By Tier and Size of companies)
         14.2 Market Share Analysis By Company, 2016
         14.3 Company Profiles 
                 14.3.1 Johnson & Johnson (Janssen Global Services, LLC)
                          14.3.1.1 Overview
                          14.3.1.2 Financials
                          14.3.1.3 Recent Developments
                          14.3.1.4 Strategy
                 14.3.2. Boehringer Ingelheim GmbH
                          14.3.2.1 Overview
                          14.3.2.2 Financials
                          14.3.2.3 Recent Developments
                          14.3.2.4 Strategy
                 14.3.3 NeuroMetrix, Inc.
                          14.3.3.1 Overview
                          14.3.3.2 Financials
                          14.3.3.3 Recent Developments
                          14.3.3.4 Strategy
                 14.3.4 Eli Lilly and Company
                          14.3.4.1 Overview
                          14.3.4.2 Financials
                          14.3.4.3 Recent Developments
                          14.3.4.4 Strategy
                 14.3.5 GlaxoSmithKline plc.
                          14.3.5.1 Overview
                          14.3.5.2 Financials
                          14.3.5.3 Recent Developments
                          14.3.5.4 Strategy
                 14.3.6 Lupin Limited
                          14.3.6.1 Overview
                          14.3.6.2 Financials
                          14.3.6.3 Recent Developments
                          14.3.6.4 Strategy
                 14.3.7 Pfizer Inc.
                          14.3.7.1 Overview
                          14.3.7.2 Financials
                          14.3.7.3 Recent Developments
                          14.3.7.4 Strategy
                 14.3.8 Astellas Pharma Inc.,
                          14.3.8.1 Overview
                          14.3.8.2 Financials
                          14.3.8.3 Recent Developments
                          14.3.8.4 Strategy
                 14.3.9 Glenmark Pharmaceuticals Ltd
                          14.3.9.1 Overview
                          14.3.9.2 Financials
                                     14.3.13.3 Recent Developments
                          14.3.9.4 Strategy
                 14.3.10 Arbor Pharmaceuticals, LLC
                          14.3.10.1 Overview
                          14.3.10.2 Financials
                          14.3.13.3 Recent Developments
                          14.3.10.4 Strategy
                 14.3.11 Depomed, Inc.
                          14.3.10.1 Overview
                          14.3.10.2 Financials
                          14.3.13.3 Recent Developments
                          14.3.10.4 Strategy

    List of Tables

    Table 1: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Disorder Type, 2015–2025
    Table 2: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Treatment Type, 2015–2025
    Table 3: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Drug Type, 2015–2025
    Table 4: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Analgesic Drug Type, 2015–2025
    Table 5: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Topical Drug Type, 2015–2025
    Table 6: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Opioid Drug Type, 2015–2025
    Table 7: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by NSAID Type, 2015–2025
    Table 8: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Antidepressant Drug Type, 2015–2025
    Table 9: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by TCA Drug Type, 2015–2025
    Table 10: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by SNRI Drug Type, 2015–2025
    Table 11: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by SSRI Drug Type, 2015–2025
    Table 12: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Anticonvulsant Drug Type, 2015–2025
    Table 13: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Radiotherapy, 2015–2025
    Table 14: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 15: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Region, 2015–2025
    Table 16: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Country, 2015–2025
    Table 17: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Disorder Type, 2015–2025
    Table 18: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Treatment Type, 2015–2025
    Table 19: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Drug Type, 2015–2025
    Table 20: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Analgesic Drug Type, 2015–2025
    Table 21: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Topical Drug Type, 2015–2025
    Table 22: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Opioid Drug Type, 2015–2025
    Table 23: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by NSAID Type, 2015–2025
    Table 24: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Antidepressant Drug Type, 2015–2025
    Table 25: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by TCA Drug Type, 2015–2025
    Table 26: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by SNRI Drug Type, 2015–2025
    Table 27: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by SSRI Drug Type, 2015–2025
    Table 28: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Anticonvulsant Drug Type, 2015–2025
    Table 29: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Radiotherapy, 2015–2025
    Table 30: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 31: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Country, 2015–2025
    Table 32: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Disorder Type, 2015–2025
    Table 33: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Treatment Type, 2015–2025
    Table 34: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Drug Type, 2015–2025
    Table 35: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Analgesic Drug Type, 2015–2025
    Table 36: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Topical Drug Type, 2015–2025
    Table 37: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Opioid Drug Type, 2015–2025
    Table 38: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by NSAID Type, 2015–2025
    Table 39: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Antidepressant Drug Type, 2015–2025
    Table 40: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by TCA Drug Type, 2015–2025
    Table 41: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by SNRI Drug Type, 2015–2025
    Table 42: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by SSRI Drug Type, 2015–2025
    Table 43: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Anticonvulsant Drug Type, 2015–2025
    Table 44: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Radiotherapy, 2015–2025
    Table 45: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 46: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Country, 2015–2025
    Table 47: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Disorder Type, 2015–2025
    Table 48: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Treatment Type, 2015–2025
    Table 49: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Drug Type, 2015–2025
    Table 50: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Analgesic Drug Type, 2015–2025
    Table 51: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Topical Drug Type, 2015–2025
    Table 52: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Opioid Drug Type, 2015–2025
    Table 53: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by NSAID Type, 2015–2025
    Table 54: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Antidepressant Drug Type, 2015–2025
    Table 55: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by TCA Drug Type, 2015–2025
    Table 56: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by SNRI Drug Type, 2015–2025
    Table 57: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by SSRI Drug Type, 2015–2025
    Table 58: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Anticonvulsant Drug Type, 2015–2025
    Table 59: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Radiotherapy, 2015–2025
    Table 60: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 61: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Country, 2015–2025
    Table 62: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Disorder Type, 2015–2025
    Table 63: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Treatment Type, 2015–2025
    Table 64: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Drug Type, 2015–2025
    Table 65: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Analgesic Drug Type, 2015–2025
    Table 66: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Topical Drug Type, 2015–2025
    Table 67: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Opioid Drug Type, 2015–2025
    Table 68: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by NSAID Type, 2015–2025
    Table 69: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Antidepressant Drug Type, 2015–2025
    Table 70: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by TCA Drug Type, 2015–2025
    Table 71: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by SNRI Drug Type, 2015–2025
    Table 72: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by SSRI Drug Type, 2015–2025
    Table 73: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Anticonvulsant Drug Type, 2015–2025
    Table 74: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Radiotherapy, 2015–2025
    Table 75: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 76: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Country, 2015–2025
    Table 77: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Disorder Type, 2015–2025
    Table 78: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Treatment Type, 2015–2025
    Table 79: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Drug Type, 2015–2025
    Table 80: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Analgesic Drug Type, 2015–2025
    Table 81: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Topical Drug Type, 2015–2025
    Table 82: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Opioid Drug Type, 2015–2025
    Table 83: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by NSAID Type, 2015–2025
    Table 84: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Antidepressant Drug Type, 2015–2025
    Table 85: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by TCA Drug Type, 2015–2025
    Table 86: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by SNRI Drug Type, 2015–2025
    Table 87: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by SSRI Drug Type, 2015–2025
    Table 88: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Anticonvulsant Drug Type, 2015–2025
    Table 89: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Radiotherapy, 2015–2025
    Table 90: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025

    List of Figures

    Figure 1: Global Diabetic Neuropathy, Market Size (US$ Mn) Forecast, 2015–2025
    Figure 2: Global Diabetic Neuropathy Market Value Share, by Disorder Type, for 2017 and 2025
    Figure 3: Global Diabetic Neuropathy Market Attractiveness Analysis, by Disorder Type, 2017–2025
    Figure 4: Global Peripheral Neuropathy Market Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2015–2025
    Figure 5: Global Autonomic Neuropathy Market Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2015–2025
    Figure 6: Global Proximal Neuropathy Market Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2015–2025
    Figure 7: Global Focal Neuropathy Market Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2015–2025
    Figure 8: Global Diabetic Neuropathy Market Value Share, by Treatment Type, 2017 and 2025
    Figure 9: Global Diabetic Neuropathy Market Attractiveness Analysis, by Treatment Type, 2017–2025
    Figure 10: Global Analgesic Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
    Figure 11: Global Antidepressant Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
    Figure 12: Global Anticonvulsant Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
    Figure 13: Global Other Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
    Figure 14: Global Diabetic Neuropathy Market Value Share, by Distribution Channel, 2017 and 2025
    Figure 15: Global Diabetic Neuropathy Market Attractiveness Analysis, by Distribution Channel, 2017–2025
    Figure 16: Global Diabetic Neuropathy Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospitals, 2015–2025
    Figure 17: Global Diabetic Neuropathy Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Clinics, 2015–2025
    Figure 18: Global Diabetic Neuropathy Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacy, 2015–2025
    Figure 19: Global Diabetic Neuropathy Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacy, 2015–2025
    Figure 20: Global Diabetic Neuropathy Market Value Share, by Region, 2017 and 2025
    Figure 21: Global Diabetic Neuropathy Market Attractiveness Analysis, by Region, 2016–2024
    Figure 22: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
    Figure 23: North America Diabetic Neuropathy Market Value Share, by Country, 2017 and 2025
    Figure 24: North America Diabetic Neuropathy Market Attractiveness, by Country, 2017–2025
    Figure 25: North America Diabetic Neuropathy Market Value Share, by Disorder Type, 2017 and 2025
    Figure 26: North America Diabetic Neuropathy Market Attractiveness, by Disorder Type, 2017–2025
    Figure 27: North America Diabetic Neuropathy Market Value Share, by Treatment Type, 2017 and 2025
    Figure 28: North America Diabetic Neuropathy Market Attractiveness, by Treatment Type, 2017–2025
    Figure 29: North America Diabetic Neuropathy Market Value Share, by Distribution Channel, 2017 and 2025
    Figure 30: North America Diabetic Neuropathy Market Attractiveness, by Distribution Channel, 2017–2025
    Figure 31: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2025
    Figure 32: Europe Diabetic Neuropathy Market Value Share, by Country, 2017 and 2025
    Figure 33: Europe Diabetic Neuropathy Market Attractiveness, by Country, 2017–2025
    Figure 34: Europe Diabetic Neuropathy Market Value Share, by Disorder Type, 2017 and 2025
    Figure 35: Europe Diabetic Neuropathy Market Attractiveness, by Disorder Type, 2017–2025
    Figure 36: Europe Diabetic Neuropathy Market Value Share, by Treatment Type, 2017 and 2025
    Figure 37: Europe Diabetic Neuropathy Market Attractiveness, by Treatment Type, 2017–2025
    Figure 38: Europe Diabetic Neuropathy Market Value Share, by Distribution Channel, 2017 and 2025
    Figure 39: Europe Diabetic Neuropathy Market Attractiveness, by Distribution Channel, 2017–2025
    Figure 40: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast and Y-o-Y Growth Projections (%), 2015–2025
    Figure 41: Asia Pacific Diabetic Neuropathy Market Value Share, by Country, 2017 and 2025
    Figure 42: Asia Pacific Diabetic Neuropathy Market Attractiveness, by Country, 2017–2025
    Figure 43: Asia Pacific Diabetic Neuropathy Market Value Share, by Disorder Type, 2017 and 2025
    Figure 44: Asia Pacific Diabetic Neuropathy Market Attractiveness, by Disorder Type, 2017–2025
    Figure 45: Asia Pacific Diabetic Neuropathy Market Value Share, by Treatment Type, 2017 and 2025
    Figure 46: Asia Pacific Diabetic Neuropathy Market Attractiveness, by Treatment Type, 2017–2025
    Figure 47: Asia Pacific Diabetic Neuropathy Market Value Share, by Distribution Channel, 2017 and 2025
    Figure 48: Asia Pacific Diabetic Neuropathy Market Attractiveness, by Distribution Channel, 2017–2025
    Figure 49: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast and Y-o-Y Growth Projections (%), 2015–2025
    Figure 50: Latin America Diabetic Neuropathy Market Value Share, by Country, 2017 and 2025
    Figure 51: Latin America Diabetic Neuropathy Market Attractiveness, by Country, 2017–2025
    Figure 52: Latin America Diabetic Neuropathy Market Value Share, by Disorder Type, 2017 and 2025
    Figure 53: Latin America Diabetic Neuropathy Market Attractiveness, by Disorder Type, 2017–2025
    Figure 54: Latin America Diabetic Neuropathy Market Value Share, by Treatment Type, 2017 and 2025
    Figure 55: Latin America Diabetic Neuropathy Market Attractiveness, by Treatment Type, 2017–2025
    Figure 56: Latin America Diabetic Neuropathy Market Value Share, by Distribution Channel, 2017 and 2025
    Figure 57: Latin America Diabetic Neuropathy Market Attractiveness, by Distribution Channel, 2017–2025
    Figure 58: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast and Y-o-Y Growth Projections (%), 2015–2025
    Figure 59: Middle East & Africa Diabetic Neuropathy Market Value Share, by Country, 2017 and 2025
    Figure 60: Middle East & Africa Diabetic Neuropathy Market Attractiveness, by Country, 2017–2025
    Figure 61: Middle East & Africa Diabetic Neuropathy Market Value Share, by Disorder Type, 2017 and 2025
    Figure 62: Middle East & Africa Diabetic Neuropathy Market Attractiveness, by Disorder Type, 2017–2025
    Figure 63: Middle East & Africa Diabetic Neuropathy Market Value Share, by Treatment Type, 2017 and 2025
    Figure 64: Middle East & Africa Diabetic Neuropathy Market Attractiveness, by Treatment Type, 2017–2025
    Figure 65: Middle East & Africa Diabetic Neuropathy Market Value Share, by Distribution Channel, 2017 and 2025
    Figure 66: Middle East & Africa Diabetic Neuropathy Market Attractiveness, by Distribution Channel, 2017–2025
    Figure 67: Global Diabetic Neuropathy Market Share Analysis, by Company, 2016

Copyright © Transparency Market Research, Inc. All Rights reserved